iShares Edge U.S. Fixed Income Balanced Risk ETF FIBR 深 沪
等待开盘 10-09 09:30:00 美东时间
89.2953
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 89.2953
- 总市值 7590.10万
- 52周最高 88.5542
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 82.6013
- 委 比 0.00%
- 总股本 85.00万
- 历史最高 88.5542
- 量 比 0
- 振 幅 0.00%
- 历史最低 67.6538
- 每 手 1
- 风险率 2.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Garware Technical Fibres Schedules Investor Meet in Mumbai
An announcement from Garware Technical Fibres Limited ( ($IN:GARFIBRES) ) is no...
09-25 15:34
BENEFIBER MAKES FIBRE CONSUMPTION EASIER FOR CANADIANS WITH LAUNCH OF NEW PRODUCTS
The taste-free, clearly dissolving prebiotic dietary fibre easily integrates into Canadians' wellness routines, helping them get their recommended daily fibre intake TORONTO, Sept. 17, 2025 ...
09-18 00:00
SiNtx Technologies Has Received A Notice Of Allowance For A US Patent Titled "ANTIPATHOGENIC FIBROUS MATERIALS (USED ON AN ANTIVIRAL FACE MASK FOR INACTIVATING AND/OR PREVENTING THE TRANSMISSIN OF A VIRUS)"
https://patentcenter.uspto.gov/applications/17839063/ifw/docs
09-06 01:29
Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date
NASHVILLE, Tenn., Aug. 5, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved ...
08-06 04:05
FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
FibroBiologics, a biotech company, announced its Q2 2025 financial results, highlighting a $5 million financing round to support a Phase 1/2 trial for diabetic foot ulcers. Key updates include leadership expansion, promising pre-clinical data on psoriasis treatment, and manufacturing confirmation for CybroCell™. Upcoming milestones include initiating the DFU trial in early 2026. Research and development expenses rose to $3.8 million, contributing...
07-31 20:30
FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications
FibroBiologics, Inc. has filed a patent application for methods to generate multipotent cells from fibroblasts in donor tissue for clinical use. These cells can differentiate into various specialized cell types, offering potential for regenerative treatments and drug development. The innovation addresses challenges in scalable, stable cell production, expanding therapeutic possibilities.
07-28 12:30
Garware Technical Fibres Transfers Norway Operations to Subsidiary
Garware Technical Fibres Limited ( ($IN:GARFIBRES) ) has issued an update. Garw...
06-26 00:25
FibroBiologics to Present at the BIO International Convention 2025
FibroBiologics, Inc. CEO Pete O’Heeron will present a company update at the BIO International Convention 2025 on June 17, 2025, at 10:45 a.m. ET in Boston. The presentation will highlight recent corporate milestones and research advances using fibroblast-based technology for chronic diseases, including wound healing, multiple sclerosis, and psoriasis. FibroBiologics is advancing therapies targeting underlying biological dysfunction rather than sy...
06-16 13:50
Cumberland Pharmaceuticals And Qureight Partner To Advance Idiopathic Pulmonary Fibrosis Treatment Research
Cumberland leveraging Qureight's deep-learning AI platform for its Phase II FIGHTING FIBROSIS™ clinical trial
05-14 04:17
CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH
Cumberland leveraging Qureight's deep-learning AI platform for its Phase II FIGHTING FIBROSIS™ clinical trial NASHVILLE, Tenn. and CAMBRIDGE, England, May 13, 2025 /PRNewswire/ -- Cumberlan...
05-14 04:05
